Successfully Validate Novel Targets, Improve Preclinical Predictability of Patient-Derived Models and Optimize Drug Pharmacology to Accelerate Translation of Robust Protein Misfolding Targeted Therapeutics into the Clinic. With numerous molecular approaches emerging that demonstrate viable efficacy of targeting protein misfolding and aggregation, join the Protein Misfolding Drug Discovery Summit - the only industry and translational focused conference dedicated to the discovery and translation of disruptive disease-modifying therapeutics with optimized pharmacology to target protein misfolding in proteopathies and cancer.
conference + 2 workshops (Industry): USD 4097.00,
conference + 1 workshop (Industry): USD 3498.00,
conference only (Industry): USD 2899.00,
workshop only (Industry): USD 699.00
Speakers: Matthew Townsend Global Director of Proteostasis, Alzheimer's Disease AbbVie, Christopher Missling President and CEO Anavex Life Sciences, Michele Vendruscolo Professor and CSO Cambridge University Centre for Misfolding Diseases and Wren Therapeutics, Gergely Toth Founder and CEO CantaBio Pharmaceuticals, Suchira Bose Research Advisor and Head of Molecular Pathology, Neuroscience Eli Lilly, David Lynn HHMI Professor Emory University, Zhexing Wen Assistant Professor Emory University, Peter Lansbury CSO Lysosomal Therapeutics, Aubin Michalon Principal Scientist Neurimmune, Rick Morimoto Professor Northwestern University, Neil Cashman CSO and Co-Founder ProMIS Neurosciences, Wagner Zago CSO Prothena, Judith Frydman Professor Stanford University, Marcia Taylor VP Research and Neurodegeneration Alliance Manager Treventis, David Smith Associate Professor West Virginia University, Johnny Habchi Head of Research Wren Therapeutics, Kenneth Rhodes CSO Yumanity
Time: 9:00 am to 5:00 pm